Physician profile
Perry J Larimer
NPI 1891752218
$2,631.65
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $473 · 2021: $491 · 2023: $628 · 2024: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $293.52 | 2019-2021 | |
| Urogen Pharma, INC. | $276.44 | 2021-2023 | Jelmyto |
| Myriad Genetic Laboratories, INC. | $248.65 | 2024 | Prolaris |
| Teleflex LLC | $180.53 | 2024 | |
| Dendreon Pharmaceuticals LLC | $175.87 | 2019-2023 | Provenge |
| Intuitive Surgical, INC. | $164.33 | 2024 | |
| Boston Scientific Corporation | $140.93 | 2019-2021 | |
| Blue Earth Diagnostics | $136.68 | 2020-2021 | |
| Pfizer INC. | $135.07 | 2019 | |
| Procept Biorobotics Corporation | $107.14 | 2021 | |
| Clarus Therapeutics INC. | $103.09 | 2020 | |
| Amgen INC. | $100.03 | 2023 | Prolia |
| Progenics Pharmaceuticals, INC. | $97.76 | 2023 | Pylarify |
| Sumitomo Pharma America, INC. | $95.15 | 2023 | Gemtesa |
| Rochester Medical Corporation | $74.34 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.74 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $36.42 | 2020 | |
| Coloplast Corp | $26.50 | 2019-2020 | |
| Axonics, INC. | $26.37 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $24.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.75 | 2020 | |
| Endo Pharmaceuticals INC. | $24.61 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $17.38 | 2023 | Trelstar |
| Abbvie INC. | $14.90 | 2020 | |
| Sun Pharmaceutical Industries INC. | $13.89 | 2023 | Yonsa |
| Tolmar Pharmaceuticals, INC. | $13.74 | 2020 | |
| Mission Pharmacal Company | $12.06 | 2019 | |
| Allergan, INC. | $11.79 | 2020 | |
| Janssen Biotech, INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Larimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.